Available Clinical Trials

LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy

An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

Study of Avutometinib (VS-6766) Plus Adagrasib in KRAS G12C NSCLC Patients

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Nonsquamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

A Phase III Study Assessing the Addition of Atezolizumab Immunotherapy to the Usual Radiation Treatment for Patients With Early NSCLC

A Phase I Study of NVL-655 in People With Advanced NSCLC or Other Solid Tumors

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1–4 cm

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

Crizotinib in Treating Patients With Stage IB-IIIA NSCLC That Has Been Removed by Surgery and ALK Fusion Mutations

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early NSCLC

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent NSCLC Following Immunotherapy

A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab vs Standard of Care in Stage IV or Recurrent NSCLC

A Randomized, Open-label, Phase II Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects With Advanced or Metastatic PD-L1 High NSCLC Without Actionable Genomic Alterations

A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs Placebo for Patients With Tumors Harboring the ALK Fusion Protein

A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1 and 4 cm: